Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors

The goal of this clinical trial is to evaluate the efficacy of sentinel lymph node biopsy in stage AI-IIA germ cell tumors (seminoma/nonseminoma). The main questions it aims to answer are: * To evaluate relapse-free survival during the first two years after SLNB. * To estimate the percentage of patients who did not require adjuvant treatment after primary endoscopic SLNB. * Determine the microRNA expression profile in blood plasma, evaluate miRNAs as a potential prognostic and predictive factor in patients with testicular germ cell tumors. * Assess the correlation between computed tomography and positive lymph nodes on examination. Participants will undergo: * surgical treatment including orchofuniculectomy with simultaneous laparoscopic biopsy of the sentinel lymph node using indocyanine green dye with/without methylene blue dye. * 24 hours before the procedure, a radiopharmaceutical (RP) is injected into the spermatic cord, followed by SPECT to determine the regional sentinel lymph node(s). * The level of microRNA will be examined before surgery and 10 days after surgery.